首页 › 基金 › Troluce Capital Advisors LLC › STOK
Troluce Capital Advisors LLC 对 STOK 的持仓历史
STOKE THERAPEUTICS INC · 医疗保健
Troluce Capital Advisors LLC 在 Q3 2026 的 13F 申报中披露持有 STOK(STOKE THERAPEUTICS INC)806,108 股,市值约 US$21.0M,约占其申报组合的 2.83%,在其申报持仓中市值排名第 13 位。 Troluce Capital Advisors LLC 最近 3 个申报季度中有 3 个季度披露了 STOK 持仓,最早可追溯至 Q1 2026。
最后更新: 2026-11-17 · 来源: SEC EDGAR Form 13F-HR
Troluce Capital Advisors LLC 对 STOK 的持仓演变
Troluce Capital Advisors LLC 于 Q1 2026 首次披露 STOK 持仓:652,800 股(约 US$21.3M)。 在 3 次申报中,Troluce Capital Advisors LLC 1 次增持、1 次减持、0 次保持不变。 最近一期申报(Q3 2026)显示持股 806,108 股、市值约 US$21.0M,环比增持 309,692 股。。 持仓曾出现大幅变动:Q3 2026 增持约 62% (随后一个季度股价上涨 2%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q1 2026 | 652.80K | $21.26M | 新进 |
| Q2 2026 | 496.42K | $16.24M | 减持 |
| Q3 2026 | 806.11K | $20.96M | 增持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 STOK 与 13F 数据
STOK(STOKE THERAPEUTICS INC)属于医疗保健行业。我们追踪的基金中还有 47 只申报持有 STOK,申报仓位最大的包括:RTW INVESTMENTS, LP (US$146.2M), Lynx1 Capital Management LP (US$101.3M), Redmile Group, LLC (US$100.6M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 STOK 的基金
- RTW INVESTMENTS, LP 5.62M 股 · $146.21M · Q3 2026
- Lynx1 Capital Management LP 3.90M 股 · $101.30M · Q3 2026
- Redmile Group, LLC 3.87M 股 · $100.59M · Q3 2026
- BVF INC/IL 3.61M 股 · $93.83M · Q3 2026
- Siren, L.L.C. 2.00M 股 · $51.88M · Q3 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 1.82M 股 · $47.41M · Q3 2026
- BAKER BROS. ADVISORS LP 1.31M 股 · $34.16M · Q3 2026
- MPM BioImpact LLC 925.13K 股 · $24.05M · Q3 2026
- Opaleye Management Inc. 700.00K 股 · $22.90M · Q2 2026
- EcoR1 Capital, LLC 835.00K 股 · $21.71M · Q3 2026
- Vestal Point Capital, LP 345.00K 股 · $8.97M · Q3 2026
- TANG CAPITAL MANAGEMENT LLC 300.00K 股 · $7.80M · Q3 2026
更多关于 Troluce Capital Advisors LLC
常见问题
How long has Troluce Capital Advisors LLC held STOK?
Troluce Capital Advisors LLC has disclosed STOK holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Troluce Capital Advisors LLC's current position in STOK?
As of Q3 2026, Troluce Capital Advisors LLC holds 806.11K shares of STOK (STOKE THERAPEUTICS INC), valued at $20.96M, representing 2.83% of its reported portfolio and ranking #13.
Has Troluce Capital Advisors LLC been buying or selling STOK?
In the latest 13F filing (Q3 2026), Troluce Capital Advisors LLC increased its position in STOK.
Which other funds hold STOK?
Other major institutional holders of STOK include RTW INVESTMENTS, LP, Lynx1 Capital Management LP, Redmile Group, LLC, among 47 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.